Create a Report

Please provide report title
Please provide location
Please provide details

Get alerts and updates for your case!

This information is not shown on the website. We can notify you of updates, and may contact you for more information to help resolve or follow up on your issue.

Please provide email or phone
Please provide email or phone

We do not show your email or contact info

Skip this step

Add photos or video

We recommend photos and videos to help explain your report

Add Photo/Video
Drop files here
Skip this step

Email or SMS copy of report

Enter below to get emailed a copy of your report, or sms a link to your report

Please provide email or phone
Please provide email or phone

Thank you for your report!

The report was
successfully sent!


Your report is queued - it may take up to 12 hours to process your report.


Email us at support@safelyhq.com if you have questions.

Report by

Safety Report: Bayshore Pharmaceuticals, LLS Metformin Hydrochloride Extended-Release Tablets USP, 500 mg & 750 mg - recalled due to Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity, United States

4 years ago source fda.gov

Recall notice

United States

Company name: Bayshore Pharmaceuticals, LLS
Brand name: Bayshore Pharmaceuticals, LLS
Product recalled: Metformin Hydrochloride Extended-Release Tablets USP, 500 mg & 750 mg
Reason of the recall: Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
FDA Recall date: August 20, 2020
Recall details: Company Announcement Bayshore Pharmaceuticals, LLC, Short Hills, NJ is voluntarily recalling one (1) lot of Metformin Hydrochloride Extended-Release Tablets USP, 500 mg, 1000 count bottles and one (1) lot of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, 100 count bottles within expiry to the consumer level due to the detection of N-Nitrosodimethylamine (NDMA) levels above the Acceptable Daily Intake Limit. This product was manufactured by Beximco Pharmaceuticals Limited, Dhaka, Bangladesh in June 2019, for U.S. distribution by Bayshore. Bayshore was notified by the U.S. Food and Drug Administration (US FDA) that one lot (Lot number 18657) of Metformin Hydrochloride Extended-Release Tablets, USP 750 mg was tested and showed results for N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit (ADI) and recommended recall of the one tested lot. Bayshore has agreed to recall this lot, and out of an abundance of caution, the company has tested samples from eight (8) lots of Metformin Hydrochloride Extended-Release Tablets manufactured using same API lot of the failed lot. Out of eight (8) lots, one lot (Lot number 18657) of Metformin Hydrochloride Extended-Release Tablets, USP 750 mg and one lot (Lot number 18641) of Metformin Hydrochloride Extended-Release Tablets, USP 500 mg have showed N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit (ADI). Hence, Bayshore has decided to recall the two lots (Lot number 18641 and 18657). To date, neither Bayshore nor Beximco have received any reports of adverse events related to use of the product. Risk Statement: NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables. Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 750 mg are indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Patients who have received impacted lots of Metformin Hydrochloride Extended-Release Tablets, USP 500 mg and 750 mg are advised to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment.  According to the FDA, it could be dangerous for patients with this serious condition to stop taking their Metformin without first talking to their healthcare professionals.  Please visit the agency’s website for more information at www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin. The Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 750 mg lots subject to the recall are identified in the table below.
Check the full recall details on www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bayshore-pharmaceuticals-llc-issues-voluntary-nationwide-recall-metformin-hydrochloride-extended
Source: FDA

#drugs #blood #us #sugar

Recent Interesting Reports

A package from that same address arrived at my home. I ordered a hair straightener from an ad on Facebook. It took two months to arrive, however there is no address, phone number or email to consult with issues. There is no manufacturer name on the box even. No one to refer questions to

#scam #facebookscam #delivery #jerseycity #newjersey #us

I received two packages I did not order with this return address. I received two separate packages, each containing a very low quality graduation greeting card. I did not order these, and I have no idea what company sent them, but I think this might be a… See more

#unorderedpackage #delivery #whittierboulevard #losangeles #california #us

Weird package with cardboard picture sent by deceased Set 21 2024 H. Kinney
Like all the others, I received a package containing a 3 inch by 3 inch cardboard with a picture on one side and paper on the other. I see so many other writing in… See more

#emptypackage #delivery #10175harwindrive #houston #texas #us